close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Design Therapeutics, Inc.

News headline image
Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Participate in Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Participate in Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers CMPS DSGN XENE
News headline image
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
News headline image
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.